vs
Side-by-side financial comparison of G III APPAREL GROUP LTD (GIII) and Organon & Co. (OGN). Click either name above to swap in a different company.
Organon & Co. is the larger business by last-quarter revenue ($1.5B vs $988.6M, roughly 1.5× G III APPAREL GROUP LTD). Organon & Co. runs the higher net margin — 10.0% vs 8.2%, a 1.8% gap on every dollar of revenue. On growth, Organon & Co. posted the faster year-over-year revenue change (-3.5% vs -9.0%). Over the past eight quarters, G III APPAREL GROUP LTD's revenue compounded faster (13.7% CAGR vs -4.7%).
G III Apparel Group is a global fashion company that designs, sources, manufactures, markets and distributes apparel, footwear, and accessories under a range of owned and licensed well-known brands. It serves department stores, specialty retailers, and e-commerce platforms across North America, Europe, and other key global markets, catering to casual, sportswear, and premium fashion consumer segments.
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.
GIII vs OGN — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $988.6M | $1.5B |
| Net Profit | $80.6M | $146.0M |
| Gross Margin | 38.6% | 53.6% |
| Operating Margin | 11.4% | — |
| Net Margin | 8.2% | 10.0% |
| Revenue YoY | -9.0% | -3.5% |
| Net Profit YoY | -29.8% | 67.8% |
| EPS (diluted) | $1.84 | $0.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $1.5B | ||
| Q4 25 | $988.6M | $1.5B | ||
| Q3 25 | $613.3M | $1.6B | ||
| Q2 25 | $583.6M | $1.6B | ||
| Q1 25 | $839.5M | $1.5B | ||
| Q4 24 | $1.1B | $1.6B | ||
| Q3 24 | $644.8M | $1.6B | ||
| Q2 24 | $609.7M | $1.6B |
| Q1 26 | — | $146.0M | ||
| Q4 25 | $80.6M | $-205.0M | ||
| Q3 25 | $10.9M | $160.0M | ||
| Q2 25 | $7.8M | $145.0M | ||
| Q1 25 | $48.8M | $87.0M | ||
| Q4 24 | $114.8M | $109.0M | ||
| Q3 24 | $24.2M | $359.0M | ||
| Q2 24 | $5.8M | $195.0M |
| Q1 26 | — | 53.6% | ||
| Q4 25 | 38.6% | 49.2% | ||
| Q3 25 | 40.8% | 53.5% | ||
| Q2 25 | 42.2% | 54.8% | ||
| Q1 25 | 39.5% | 55.6% | ||
| Q4 24 | 39.8% | 56.3% | ||
| Q3 24 | 42.8% | 58.3% | ||
| Q2 24 | 42.5% | 58.4% |
| Q1 26 | — | — | ||
| Q4 25 | 11.4% | -9.8% | ||
| Q3 25 | 2.7% | 15.2% | ||
| Q2 25 | 1.5% | 14.4% | ||
| Q1 25 | 8.5% | 6.7% | ||
| Q4 24 | 15.3% | 8.1% | ||
| Q3 24 | 6.4% | 13.1% | ||
| Q2 24 | 2.2% | 14.6% |
| Q1 26 | — | 10.0% | ||
| Q4 25 | 8.2% | -13.6% | ||
| Q3 25 | 1.8% | 10.0% | ||
| Q2 25 | 1.3% | 9.1% | ||
| Q1 25 | 5.8% | 5.8% | ||
| Q4 24 | 10.6% | 6.8% | ||
| Q3 24 | 3.8% | 22.7% | ||
| Q2 24 | 1.0% | 12.1% |
| Q1 26 | — | $0.55 | ||
| Q4 25 | $1.84 | $-0.78 | ||
| Q3 25 | $0.25 | $0.61 | ||
| Q2 25 | $0.17 | $0.56 | ||
| Q1 25 | $1.00 | $0.33 | ||
| Q4 24 | $2.55 | $0.42 | ||
| Q3 24 | $0.53 | $1.38 | ||
| Q2 24 | $0.12 | $0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $184.1M | — |
| Total DebtLower is stronger | $6.5M | — |
| Stockholders' EquityBook value | $1.8B | — |
| Total Assets | $2.8B | — |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $184.1M | $574.0M | ||
| Q3 25 | $301.8M | $672.0M | ||
| Q2 25 | $257.8M | $599.0M | ||
| Q1 25 | $181.4M | $547.0M | ||
| Q4 24 | $104.7M | $675.0M | ||
| Q3 24 | $414.8M | $763.0M | ||
| Q2 24 | $508.4M | $704.0M |
| Q1 26 | — | — | ||
| Q4 25 | $6.5M | $8.6B | ||
| Q3 25 | $6.9M | $8.8B | ||
| Q2 25 | $6.8M | $8.9B | ||
| Q1 25 | $3.0M | $9.0B | ||
| Q4 24 | $213.9M | $8.9B | ||
| Q3 24 | $402.5M | $8.7B | ||
| Q2 24 | $402.7M | $8.7B |
| Q1 26 | — | — | ||
| Q4 25 | $1.8B | $752.0M | ||
| Q3 25 | $1.7B | $906.0M | ||
| Q2 25 | $1.7B | $733.0M | ||
| Q1 25 | $1.7B | $542.0M | ||
| Q4 24 | $1.6B | $472.0M | ||
| Q3 24 | $1.5B | $493.0M | ||
| Q2 24 | $1.5B | $144.0M |
| Q1 26 | — | — | ||
| Q4 25 | $2.8B | $12.9B | ||
| Q3 25 | $2.7B | $13.6B | ||
| Q2 25 | $2.4B | $13.5B | ||
| Q1 25 | $2.5B | $13.2B | ||
| Q4 24 | $2.8B | $13.1B | ||
| Q3 24 | $2.7B | $12.8B | ||
| Q2 24 | $2.6B | $12.2B |
| Q1 26 | — | — | ||
| Q4 25 | 0.00× | 11.49× | ||
| Q3 25 | 0.00× | 9.74× | ||
| Q2 25 | 0.00× | 12.14× | ||
| Q1 25 | 0.00× | 16.52× | ||
| Q4 24 | 0.13× | 18.81× | ||
| Q3 24 | 0.27× | 17.75× | ||
| Q2 24 | 0.26× | 60.11× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-97.3M | — |
| Free Cash FlowOCF − Capex | $-106.4M | — |
| FCF MarginFCF / Revenue | -10.8% | — |
| Capex IntensityCapex / Revenue | 0.9% | — |
| Cash ConversionOCF / Net Profit | -1.21× | — |
| TTM Free Cash FlowTrailing 4 quarters | $367.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-97.3M | $141.0M | ||
| Q3 25 | $75.1M | $264.0M | ||
| Q2 25 | $93.8M | $220.0M | ||
| Q1 25 | $333.4M | $75.0M | ||
| Q4 24 | $-111.8M | $390.0M | ||
| Q3 24 | $49.3M | $141.0M | ||
| Q2 24 | $45.5M | $332.0M |
| Q1 26 | — | — | ||
| Q4 25 | $-106.4M | $96.0M | ||
| Q3 25 | $64.7M | $218.0M | ||
| Q2 25 | $85.7M | $181.0M | ||
| Q1 25 | $323.7M | $43.0M | ||
| Q4 24 | $-120.3M | $335.0M | ||
| Q3 24 | $38.8M | $99.0M | ||
| Q2 24 | $32.8M | $300.0M |
| Q1 26 | — | — | ||
| Q4 25 | -10.8% | 6.4% | ||
| Q3 25 | 10.6% | 13.6% | ||
| Q2 25 | 14.7% | 11.4% | ||
| Q1 25 | 38.6% | 2.8% | ||
| Q4 24 | -11.1% | 21.0% | ||
| Q3 24 | 6.0% | 6.3% | ||
| Q2 24 | 5.4% | 18.7% |
| Q1 26 | — | — | ||
| Q4 25 | 0.9% | 3.0% | ||
| Q3 25 | 1.7% | 2.9% | ||
| Q2 25 | 1.4% | 2.4% | ||
| Q1 25 | 1.2% | 2.1% | ||
| Q4 24 | 0.8% | 3.5% | ||
| Q3 24 | 1.6% | 2.7% | ||
| Q2 24 | 2.1% | 2.0% |
| Q1 26 | — | — | ||
| Q4 25 | -1.21× | — | ||
| Q3 25 | 6.86× | 1.65× | ||
| Q2 25 | 12.09× | 1.52× | ||
| Q1 25 | 6.83× | 0.86× | ||
| Q4 24 | -0.97× | 3.58× | ||
| Q3 24 | 2.04× | 0.39× | ||
| Q2 24 | 7.84× | 1.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GIII
| Proprietary Brands | $498.1M | 50% |
| Licensed Brands | $479.2M | 48% |
| Retail Segment | $45.7M | 5% |
OGN
| Established Brands | $880.0M | 60% |
| Women’s Health | $389.0M | 27% |
| Biosimilars | $173.0M | 12% |
